Important pharmacy news and late-breaking industry information updated daily.

New analyses of Pfizer and BioNTech's coronavirus vaccine indicate strong protection against COVID-19 within about 10 days of the first dose, much sooner than initially thought. Efficacy is about 52% with the first dose, then reaches about 95% with the second, the evidence shows.

Under a health care provider’s request, patients can now collect a home sample for combination COVID-19 and influenza testing and send it to Quest Diagnostic laboratory for analysis.

In England, a 90-year-old grandmother named Maggie Keenan and an 81-year-old man named William Shakespeare have become the first and second non-trial recipients of Pfizer's COVID-19 vaccine.

New treatments for sickle cell disease, including gene editing, are in the works after a decades-long lull in drug development for the condition primarily affecting African Americans.

In August, HHS announced that it expanded pharmacists’ authority to immunize children ages 3 to 18 years with vaccines recommended by CDC’s Advisory Committee on Immunization Practices (ACIP) and authorized or licensed by FDA. This will include the COVID-19 vaccine.

The drugmaker Moderna said on Wednesday that it would soon begin testing its coronavirus vaccine in children aged 12 years through 17 years. The study is to include 3,000 children, with one-half receiving two shots of vaccine 4 weeks apart, and one-half getting placebo shots of salt water.

The U.K. became the first Western nation to grant emergency-use authorization for a COVID-19 vaccine, clearing a shot developed by Pfizer and BioNTech SE to be distributed in limited numbers within days.

Despite expectations that CDC’s Advisory Committee on Immunization Practices (ACIP) would make its COVID-19 vaccine allocation recommendations once one or more vaccines received FDA emergency use authorization (EUA)—the traditional timeline—the group will vote Tuesday, December 1, on a “Phase 1a” distribution strategy. ACIP convened the 2:00 pm ET December 1 emergency meeting to ensure its advice is available before FDA approves any EUAs; the agency is slated to consider the first application on December 10. U.S. Department of Health and Human Services Secretary Alex Azar has said that Operation Warp Speed will begin shipping COVID-19 vaccines to states within 24 hours of their approval. 

Roughly 750 participants tuned in for 2 days of virtual education, video chats, networking events, and more at the Joint Federal Pharmacy Seminar (JFPS) 2020 Virtual, held on November 13 and 14.

Moderna announced Monday it has applied to FDA for emergency use authorization of its candidate COVID-19 vaccine. If approved, the company said, vaccinations could begin in the United States as soon as December 21. Moderna reported that complete data from a large study indicated the vaccine was 94.1% effective, confirming earlier estimates.